Crohn DiseasePhase 1TRIBUTENCT03185000
Treg Immunotherapy in Crohn's Disease
A Phase 1 study testing TR004 (Treg immunotherapy) in people with Crohn Disease, run by King's College London at 1 site in United Kingdom.
Trial summary
Crohn's Disease (CD) is a condition that causes inflammation of the digestive system or gut. Crohn's can affect any part of the gut, though the most common area affected is the end of the ileum (the last part of the small intestine), or the colon. Crohn's is a chronic condition. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Crohn Disease
- What is being tested?
- TR004 (Treg immunotherapy)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 4 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 8 Aug 2022to 30 Jun 2025
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Able and willing to provide written informed consent and able to comply with the protocol requirements
- Male or female aged between 18 and 80 (inclusive) years of age at date of consent
- A diagnosis of Crohn's disease (CD) established ≥12 weeks prior to date of consent by standard clinical, radiological, endoscopic and histological criteria
- Documented moderate-to-severe CD with a Crohn's Disease Activity Index (CDAI) >= 220 within 3 months of date of consent
- Active CD (mucosal inflammation) including ulceration, as assessed by colonoscopy at screening
- Failure to tolerate or to respond to at least 2 prior lines of standard CD medication intended to induce or maintain remission, as determined by the referring gastroenterologist. Examples of such medications include, but are not limited to, azathioprine, mercaptopurine, methotrexate, vedolizumab, ustekinumab or anti-tumour necrosis factor antibody therapy. This does not include steroids and 5-ASA medications
Show all 11Show fewer
- Stable doses of concomitant medications
- Normal or non-clinically significant electrocardiogram (ECG), as assessed by the Investigator at screening
- Negative stool test for Clostridium difficile and faecal culture for standard pathogens at screening. For non-pathogenic organism, inclusion will be at the discretion of the Principal Investigator (PI)
- Negative serology for HIV, Hepatitis B (cAb and sAg), Hepatitis C, HTLV and Syphilis at screening
- Subject is judged by the principal investigator to be in otherwise good health based upon the results of all screening investigations in combination with medical history and physical examination
Who cannot join
- A diagnosis of ulcerative colitis or IBD-unclassified
- CD treatment-naïve patients, defined as patients who have never received or have refused standard CD treatment
- History of clinically significant drug or alcohol abuse in the last 12 months prior to date of consent
- Any history of major immune deficiency disorder, except Crohn's disease
- Patients with a history of pulmonary embolism or deep vein thrombosis. Current or recent history (within 1 year prior to screening) of major organ or system failure or condition, acute or chronic that in the opinion of the investigator should preclude enrollment, except Crohn's disease
- History of intestinal resection or intra-abdominal surgery within 6 months prior to date of consent
Show all 30Show fewer
- Requirement for immediate or imminent surgical, endoscopic or radiological intervention for indications including (but not limited to) toxic megacolon, obstruction, massive haemorrhage, perforation, sepsis, or intra-abdominal or perianal abscess
- Patients with ileostomy or colostomy
- Patients with short bowel syndrome (less than 1.5m of small bowel)
- Complication of Crohn's disease such as strictures/stenosis, penetrating disease, or any other manifestation that might require surgery.
- Patient has received therapeutic enema or suppository, other than required for endoscopy, within 14 days prior to date of consent and/or during the screening period
- Patients who are currently using anticoagulants including but not limited to warfarin, heparin, enoxaparin, dabigatran, apixaban, rivaroxaban (note that anti-platelet agents such as aspirin up to 325mg daily or clopidogrel are permitted)
- Use of corticosteroids on the day of leukapheresis sampling, prior to the procedure. Dosing should be delayed until after the procedure has been completed. This must be checked prior to the appointment and rescheduled if use is confirmed.
- Current medically significant infection i.e. infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to date of consent or oral anti-infectives for non-Crohn's disease related infections within 14 days prior to screening visit
- Subject with an active systemic viral infection or any active viral infection that based on the investigator's clinical assessment makes the patient unsuitable for the study
- History of tuberculosis (TB), unless there is documented evidence of completion of a full course of anti-TB treatment prior to screening. For patients with latent TB, as defined by a physician specialised in TB, they must have received prophylactic treatment for 4 weeks minimum prior to dosing
- History of moderate to severe congestive heart failure (NYHA class III or IV), recent cerebrovascular accident (within 6 months of screening) and any other condition which, in the opinion of the investigator, would put the subject at risk by participation in the study
- Subject with a previous history (within 12 months of consent) of dysplasia of the gastrointestinal tract, or found to have dysplasia in any biopsy performed during the screening endoscopy unless this is deemed to be a sporadic adenoma and has been completely removed
- Significant laboratory abnormalities:
- Hb < 100g/L or WBC < 3.5 x 109/L or Plt < 100 x 109/L Creatinine > 1.5x ULN Total bilirubin > 34 µmol/L or ALT > 2x ULN or GGT > 2xULN. Elevated unconjugated bilirubin related to Gilbert's syndrome is allowed
- Anti-TNF or ustekinumab therapy within 8 weeks of study dosing (day 0). Vedolizumab therapy within 5 half-lives (15 weeks) of dosing. Exposure to cyclosporine or tacrolimus within 2 weeks of date of consent
- Patient currently receiving total parenteral nutrition (TPN) or plan to receive TPN at any time during the course of the study
- Received another investigational drug within 60 days of anticipated study date of consent or 5 half lives whichever is greater
- Patient who previously received stem cell transplantation
- Current evidence of dysplasia or history of malignancy within the last 5 years of date of consent (except successfully treated squamous cell or basal cell carcinoma, without metastases or localised carcinoma in situ of the cervix)
- Pregnant and lactating patients (females of childbearing potential with a positive serum pregnancy test at screening visit 1 or day -1 at week 0)
- Female patients of childbearing potential (i.e. not post-menopausal or surgically sterilised) who are not willing to use effective methods of contraception (included but not limited to hormonal contraception, Intrauterine devices, sexual abstinence, vasectomised partner) to prevent pregnancy or abstain from heterosexual activity for the duration of the trial up to W21 visit
- Male patients who are not willing to use an effective method of contraception (condoms) for the duration of the study up to W21 visit, when engaging in sexual activity with a female of childbearing potential
- Allergy to any component / excipients used for the manufacture of TR004
- Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study
Trial locations and contacts
1 site in 1 country.
Joanne Palmer Joyce contact
United Kingdom1 site, 1 recruiting
- Recruiting
Guy's Hospital - Guy's and St Thomas' NHS Foundation Trust
London, SE1 9RT
Peter Irving
About this study
Official title: A First in Human Feasibility Study of T Regulatory Cells (TR004) for Inflammatory Bowel Disease Using (ex Vivo) Treg Expansion
Crohn's Disease (CD) is a condition that causes inflammation of the digestive system or gut. Crohn's can affect any part of the gut, though the most common area affected is the end of the ileum (the last part of the small intestine), or the colon.
Crohn's is a chronic condition. This means that it is ongoing and life-long, although patients may have periods of good health (remission), as well as times when symptoms are more active (relapses or flare-ups).
Read more
Current available therapies frequently fail to maintain long-term remission and may be complicated by significant side effects.
There is an unmet medical need for novel therapies. Cellular therapies are emerging as potentially attractive therapeutic strategies.
The TRIBUTE trial will use autologous regulatory T cells (Tregs) expanded in vitro.
It is hoped that the administration of this treatment to patients with active CD will change the immune responses in the gut and reduce bowel wall inflammation.
Read the detailed description
The TRIBUTE trial is looking at a new type of treatment for Crohn's Disease (CD), called regulatory T-cells (Tregs) immunotherapy.
Regulatory T-cells are naturally produced by the immune system. These cells have a powerful immunosuppressive action; they prevent auto-immune diseases by suppressing the over-active response that the immune system mounts against the body in these diseases. In addition it is thought that in patients with active CD, other immune cells in the gut are resistant to the normal controlling action of Tregs. Finally, we have found that Tregs that are isolated from patients and then are grown in the laboratory are more suppressive than Tregs freshly isolated from patients' blood.
Treg immunotherapy, TR004, will be unique to each patient. White blood cells will be extracted from their blood via leukapheresis. These cells will form the starting material to manufacture TR004 by expansion in a GMP accredited laboratory following a validated manufacturing process.
It will take approximately 23 days to produce enough cells for the immunotherapy treatment.
The trial aims to recruit a total of 4 patients diagnosed with moderate to severe CD. Men and women aged over 18 years who did not tolerate or did not respond to at least 2 standard treatments for the condition will be eligible to participate.
TRIBUTE is an open label first in human feasibility study of a single dose of TR004. Four participants will receive a single dose of TR004. Participants will be dosed singly. Safety data will be collected for five weeks post administration and reviewed by the DSMB before proceeding to dose the next participant. All participants will be followed up to week 21 to collect further safety and exploratory efficacy data, with additional safety monitoring at 1 and 2 years post dose. There is one dose level - 3.0 - 5.0 million TR004/kg.
Participants will be involved in the study for up to 24 months, from screening to safety follow-up at Week 104.
Eligible participants will receive one TR004 infusion at Week 0.
Patients will have a number of blood tests over the course of the trial. This will allow the doctors to monitor how safe TR004 is and how the body reacts to it.
Other tests, including vital signs such as blood pressure, heart rate and temperature, stool testing, and colonoscopy/biopsy will also be performed for this purpose and participants will have regular check-ups by the trial team. Scans such as CT scans, MRI scans or ultrasounds may be performed prior to starting the trial and participants will fill out questionnaires and diaries to monitor their progress over the course of the trial.
There are currently no known benefits to the participants in taking part in the study. While it is hoped that the treatment will reduce bowel inflammation, this may not happen. Participants may not directly benefit from taking part in this study but the information gained from their participation may help to improve the treatments available to other people with Crohn's Disease.
During the blood tests participants may experience discomfort and there is a risk of bleeding and bruising around the puncture site but this is very rarely serious.
During leukapheresis and on infusion day cannulas will be inserted in participant's veins. The cannula insertion may cause pain, bruising, or, on rare occasions, infection.
Some people find the leukapheresis uncomfortable due to having to stay in the same position for 2-3 hours. Blood calcium level may fall during the procedure and this can cause numbness and tingling in hands and feet and around the mouth. Patients can also feel cold, dizzy or sick.
A colonoscopy poses few risks. Rarely, complications of a colonoscopy may include:
- Reaction to the sedative used during the test
- Bleeding from the site where the tissue sample (biopsy) is taken
- A tear in the colon or rectum wall (perforation). The risk of this is less than 1 in 1,000.
This is the first time this particular expanded Tregs treatment will be tested in human so there may be potential unknown risks that could be serious. The anticipated risks of Treg administration are similar to those of a blood transfusion. The potential risks are likely to be lower because the cells infused will be the patient's own cells rather than cells from a blood donor. Common transfusion symptoms include a red, itchy skin rash, swelling of the hands, arms, feet, ankles and legs, dizziness and headaches. Less common symptoms include high temperature, chills and shivering.
The TRIBUTE study will be set-up and run at Guy's and St Thomas NHS Foundation Trust, London. It will be the only UK centre recruiting participants into the study.
- Conditions
- Crohn Disease
- Being tested
- TR004 (Treg immunotherapy)
- Medical subject headings
- Crohn Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TR004 (Treg immunotherapy)Drug
Also called Autologous regulatory T cells (Tregs) expanded in vitro
Administered Intravenously (IV)
| Study group | Role | What they receive |
|---|---|---|
| Immediate ATIMP (AP) | Experimental | Patients will receive Treg immunotherapy (TR004) infusion at Week 0. Receives: Drug: TR004 (Treg immunotherapy) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of dose-limiting toxicities (DLTs)
Pre-defined safety events occurring within 5 weeks post-infusion
Measured: One period will be assessed, from Week 0 to Week 5
Secondary outcomes (4)
Disease Activity Score (CDAI / PRO-2) calculated by evaluation of patient's diary completion and colonoscopy findings
Measurement of clinical response
Measured: CDAI / PRO-2 scores will be calculated at Week 0, Week 8, Week 21
Biomarkers analysis (CRP, FCP) measured by blood test and stool sample analysis
Measurement of clinical response
Measured: CRP and FCP will be measured throughout the study, from Week 0 to Week 21
Mucosal Healing Score (SES-CD) calculated by evaluation of colonoscopy findings
Measurement of clinical response
Measured: SES-CD scores will be calculated at screening and week 8
Description of non-DLT adverse events
Pre-defined safety events occurring for the duration of the study
Measured: Week 0 to 5 and beyond week 5
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jun 2017
- Study start8 Aug 2022
- Primary completion31 Mar 2024 (estimated)
- Study completion30 Jun 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Crohn DiseaseStudies of the same condition, open and under way.
- More trials run by King's College LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 4 participants (estimated)
Sponsor and investigators
- Lead sponsor
- King's College London
- Sponsor type
- University, hospital or other
- Collaborators
- Guy's and St Thomas' NHS Foundation Trust, Medical Research Council, St. George's Hospital, London, Miltenyi biotech
- Responsible party
- Sponsor
- Investigators
- Peter Irving, Dr, Principal investigator, King's College London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03185000
- Sponsor's protocol ID
- TRIBUTE Feasibility
- Acronym
- TRIBUTE
- Status last verified
- Jan 2023
- First submitted
- 13 Apr 2017
- Last updated
- 31 Jan 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Canavan JB, Scotta C, Vossenkamper A, Goldberg R, Elder MJ, Shoval I, Marks E, Stolarczyk E, Lo JW, Powell N, Fazekasova H, Irving PM, Sanderson JD, Howard JK, Yagel S, Afzali B, MacDonald TT, Hernandez-Fuentes MP, Shpigel NY, Lombardi G, Lord GM. Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease. Gut. 2016 Apr;65(4):584-94. doi: 10.1136/gutjnl-2014-306919. Epub 2015 Feb 24.
PubMed 25715355Rodger B, Clough J, Vasconcelos J, Canavan JB, Macallan D, Prevost AT, Lord GM, Irving P. Protocol for a first-in-human feasibility study of T regulatory cells (TR004) for inflammatory bowel disease using (ex vivo) Treg expansion (TRIBUTE). BMJ Open. 2025 Jan 23;15(1):e092733. doi: 10.1136/bmjopen-2024-092733.
PubMed 39855667Goldberg R, Scotta C, Cooper D, Nissim-Eliraz E, Nir E, Tasker S, Irving PM, Sanderson J, Lavender P, Ibrahim F, Corcoran J, Prevost T, Shpigel NY, Marelli-Berg F, Lombardi G, Lord GM. Correction of Defective T-Regulatory Cells From Patients With Crohn's Disease by Ex Vivo Ligation of Retinoic Acid Receptor-alpha. Gastroenterology. 2019 May;156(6):1775-1787. doi: 10.1053/j.gastro.2019.01.025. Epub 2019 Jan 30.
PubMed 30710527
Study at a glance
From the registry record, last updated by the sponsor on 31 Jan 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A First in Human Feasibility Study of T Regulatory Cells (TR004) for Inflammatory Bowel Disease Using (ex Vivo) Treg Expansion
- ClinicalTrials.gov ID
- NCT03185000
- Acronym / sponsor ID
- TRIBUTE / TRIBUTE Feasibility
- Conditions
- Crohn Disease
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 4 participants (estimated)
- Lead sponsor
- King's College LondonUniversity, hospital or other
- Collaborators
- Guy's and St Thomas' NHS Foundation Trust, Medical Research Council, St. George's Hospital, London, Miltenyi biotech
- Study start
- 8 Aug 2022 (actual)
- Primary completion
- 31 Mar 2024 (estimated)
- Study completion
- 30 Jun 2025 (estimated)
- First posted
- 14 Jun 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Crohn's Disease (CD) is a condition that causes inflammation of the digestive system or gut. Crohn's can affect any part of the gut, though the most common area affected is the end of the ileum (the last part of the small intestine), or the colon.
Crohn's is a chronic condition. This means that it is ongoing and life-long, although patients may have periods of good health (remission), as well as times when symptoms are more active (relapses or flare-ups).
Current available therapies frequently fail to maintain long-term remission and may be complicated by significant side effects.
There is an unmet medical need for novel therapies. Cellular therapies are emerging as potentially attractive therapeutic strategies.
The TRIBUTE trial will use autologous regulatory T cells (Tregs) expanded in vitro.
It is hoped that the administration of this treatment to patients with active CD will change the immune responses in the gut and reduce bowel wall inflammation.
Detailed description
The TRIBUTE trial is looking at a new type of treatment for Crohn's Disease (CD), called regulatory T-cells (Tregs) immunotherapy.
Regulatory T-cells are naturally produced by the immune system. These cells have a powerful immunosuppressive action; they prevent auto-immune diseases by suppressing the over-active response that the immune system mounts against the body in these diseases. In addition it is thought that in patients with active CD, other immune cells in the gut are resistant to the normal controlling action of Tregs. Finally, we have found that Tregs that are isolated from patients and then are grown in the laboratory are more suppressive than Tregs freshly isolated from patients' blood.
Treg immunotherapy, TR004, will be unique to each patient. White blood cells will be extracted from their blood via leukapheresis. These cells will form the starting material to manufacture TR004 by expansion in a GMP accredited laboratory following a validated manufacturing process.
It will take approximately 23 days to produce enough cells for the immunotherapy treatment.
The trial aims to recruit a total of 4 patients diagnosed with moderate to severe CD. Men and women aged over 18 years who did not tolerate or did not respond to at least 2 standard treatments for the condition will be eligible to participate.
TRIBUTE is an open label first in human feasibility study of a single dose of TR004. Four participants will receive a single dose of TR004. Participants will be dosed singly. Safety data will be collected for five weeks post administration and reviewed by the DSMB before proceeding to dose the next participant. All participants will be followed up to week 21 to collect further safety and exploratory efficacy data, with additional safety monitoring at 1 and 2 years post dose. There is one dose level - 3.0 - 5.0 million TR004/kg.
Participants will be involved in the study for up to 24 months, from screening to safety follow-up at Week 104.
Eligible participants will receive one TR004 infusion at Week 0.
Patients will have a number of blood tests over the course of the trial. This will allow the doctors to monitor how safe TR004 is and how the body reacts to it.
Other tests, including vital signs such as blood pressure, heart rate and temperature, stool testing, and colonoscopy/biopsy will also be performed for this purpose and participants will have regular check-ups by the trial team. Scans such as CT scans, MRI scans or ultrasounds may be performed prior to starting the trial and participants will fill out questionnaires and diaries to monitor their progress over the course of the trial.
There are currently no known benefits to the participants in taking part in the study. While it is hoped that the treatment will reduce bowel inflammation, this may not happen. Participants may not directly benefit from taking part in this study but the information gained from their participation may help to improve the treatments available to other people with Crohn's Disease.
During the blood tests participants may experience discomfort and there is a risk of bleeding and bruising around the puncture site but this is very rarely serious.
During leukapheresis and on infusion day cannulas will be inserted in participant's veins. The cannula insertion may cause pain, bruising, or, on rare occasions, infection.
Some people find the leukapheresis uncomfortable due to having to stay in the same position for 2-3 hours. Blood calcium level may fall during the procedure and this can cause numbness and tingling in hands and feet and around the mouth. Patients can also feel cold, dizzy or sick.
A colonoscopy poses few risks. Rarely, complications of a colonoscopy may include:
- Reaction to the sedative used during the test
- Bleeding from the site where the tissue sample (biopsy) is taken
- A tear in the colon or rectum wall (perforation). The risk of this is less than 1 in 1,000.
This is the first time this particular expanded Tregs treatment will be tested in human so there may be potential unknown risks that could be serious. The anticipated risks of Treg administration are similar to those of a blood transfusion. The potential risks are likely to be lower because the cells infused will be the patient's own cells rather than cells from a blood donor. Common transfusion symptoms include a red, itchy skin rash, swelling of the hands, arms, feet, ankles and legs, dizziness and headaches. Less common symptoms include high temperature, chills and shivering.
The TRIBUTE study will be set-up and run at Guy's and St Thomas NHS Foundation Trust, London. It will be the only UK centre recruiting participants into the study.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Immediate ATIMP (AP) | Experimental | Drug: TR004 (Treg immunotherapy)Patients will receive Treg immunotherapy (TR004) infusion at Week 0. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Able and willing to provide written informed consent and able to comply with the protocol requirements
- Male or female aged between 18 and 80 (inclusive) years of age at date of consent
- A diagnosis of Crohn's disease (CD) established ≥12 weeks prior to date of consent by standard clinical, radiological, endoscopic and histological criteria
- Documented moderate-to-severe CD with a Crohn's Disease Activity Index (CDAI) >= 220 within 3 months of date of consent
- Active CD (mucosal inflammation) including ulceration, as assessed by colonoscopy at screening
Key exclusion criteria (30 listed)
- A diagnosis of ulcerative colitis or IBD-unclassified
- CD treatment-naïve patients, defined as patients who have never received or have refused standard CD treatment
- History of clinically significant drug or alcohol abuse in the last 12 months prior to date of consent
- Any history of major immune deficiency disorder, except Crohn's disease
- Patients with a history of pulmonary embolism or deep vein thrombosis. Current or recent history (within 1 year prior to screening) of major organ or system failure or condition, acute or chronic that in the opinion of the investigator should preclude enrollment, except Crohn's disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TR004 (Treg immunotherapy)Also: Autologous regulatory T cells (Tregs) expanded in vitroAdministered Intravenously (IV) | Drug | Immediate ATIMP (AP) |
Primary outcome
Rate of dose-limiting toxicities (DLTs)
Time frame: One period will be assessed, from Week 0 to Week 5
Pre-defined safety events occurring within 5 weeks post-infusion
4 secondary outcomes
Disease Activity Score (CDAI / PRO-2) calculated by evaluation of patient's diary completion and colonoscopy findings
Time frame: CDAI / PRO-2 scores will be calculated at Week 0, Week 8, Week 21
Biomarkers analysis (CRP, FCP) measured by blood test and stool sample analysis
Time frame: CRP and FCP will be measured throughout the study, from Week 0 to Week 21
Mucosal Healing Score (SES-CD) calculated by evaluation of colonoscopy findings
Time frame: SES-CD scores will be calculated at screening and week 8
Description of non-DLT adverse events
Time frame: Week 0 to 5 and beyond week 5
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Jan 2023.
- Background: PubMed 25715355Canavan JB, Scotta C, Vossenkamper A, Goldberg R, Elder MJ, Shoval I, Marks E, Stolarczyk E, Lo JW, Powell N, Fazekasova H, Irving PM, Sanderson JD, Howard JK, Yagel S, Afzali B, MacDonald TT, Hernandez-Fuentes MP, Shpigel NY, Lombardi G, Lord GM. Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease. Gut. 2016 Apr;65(4):584-94. doi: 10.1136/gutjnl-2014-306919. Epub 2015 Feb 24.
- Derived from this study: PubMed 39855667Rodger B, Clough J, Vasconcelos J, Canavan JB, Macallan D, Prevost AT, Lord GM, Irving P. Protocol for a first-in-human feasibility study of T regulatory cells (TR004) for inflammatory bowel disease using (ex vivo) Treg expansion (TRIBUTE). BMJ Open. 2025 Jan 23;15(1):e092733. doi: 10.1136/bmjopen-2024-092733.
- Derived from this study: PubMed 30710527Goldberg R, Scotta C, Cooper D, Nissim-Eliraz E, Nir E, Tasker S, Irving PM, Sanderson J, Lavender P, Ibrahim F, Corcoran J, Prevost T, Shpigel NY, Marelli-Berg F, Lombardi G, Lord GM. Correction of Defective T-Regulatory Cells From Patients With Crohn's Disease by Ex Vivo Ligation of Retinoic Acid Receptor-alpha. Gastroenterology. 2019 May;156(6):1775-1787. doi: 10.1053/j.gastro.2019.01.025. Epub 2019 Jan 30.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Related trials for Crohn Disease
RecruitingPhase 2
A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
Crohn's Disease
RecruitingPhase 3
A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
Crohn's Disease
RecruitingPhase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Crohn's Disease
RecruitingPhase 1/2
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
Crohn's Disease
Active, not recruitingObservational study
VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
Crohn's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Joanne Palmer Joyce contact
Peter Irving, Dr principal investigator
King's College London
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing TR004 (Treg immunotherapy) in people with Crohn Disease, run by King's College London at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 30 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 31 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Peter Irving, Dr (+44 20 7188 2499, peter.irving@gstt.nhs.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of dose-limiting toxicities (DLTs) (time frame: One period will be assessed, from Week 0 to Week 5). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03185000, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jan 2023.